N-[[1-(5-fluoropentyl)-1H-indazol-3-yl]carbonyl]-3-methyl-D-valine methyl ester (5F-ADB) is one of the most potent synthetic cannabinoids and elicits severe psychotic symptoms in humans, sometimes causing death. To investigate the neuronal mechanisms underlying its toxicity, we examined the effects of 5F-ADB on midbrain dopaminergic and serotonergic systems, which modulate various basic brain functions such as those in reward-related behavior. 5F-ADB-induced changes in spontaneous firing activity of dopaminergic and serotonergic neurons were recorded by ex vivo electrophysiological techniques. In dopaminergic neurons, 5F-ADB (1 μM) significantly increased the spontaneous firing rate, while 5F-ADB failed to activate dopaminergic neurons in the presence of the CB1 antagonist AM251 (1 μM). However, the same concentration of 5F-ADB did not affect serotonergic-neuron activity. These results suggest that 5F-ADB activates local CB1 receptors and potentiates midbrain dopaminergic systems with no direct effects on midbrain serotonergic systems.
$280.00 – $6,000.00
5F-ADB is an indazole-based synthetic cannabinoid from the indazole-3-carboxamide family, which has been used as an active ingredient in synthetic cannabis products and has been sold online as a designer drug. 5F-ADB is a potent agonist of the CB₁ receptor, though it is unclear whether it is selective for this target.
50 g, 100 g, 200 g, 300 g, 500 g, 1000 g, 2000 g, 5000 g, 10000 g
NM-2201 is an indole-based synthetic cannabinoid that presumably has similar properties to the closely related 5F-PB-22 and NNE1, which are both full agonists and unselectively bind to CB₁ and CB₂ receptors with low nanomolar affinity.
FUB-APINACA is an indazole-based synthetic cannabinoid that is presumed to be a potent agonist of the CB₁ receptor and has been sold online as a designer drug. It is an analog of APINACA and 5F-APINACA where the pentyl chain has been replaced with fluorobenzyl
SDB-005 is an indazole-based synthetic cannabinoid that has been sold online as a designer drug. It is presumed to be an agonist of the CB₁ and CB₂ cannabinoid receptors. SDB-005 is the indazole core analog of PB-22 where the 8-hydroxyquinoline has also been replaced with a naphthalene group.
MDMB-CHMICA (also incorrectly known as MMB-CHMINACA) is an indole-based synthetic cannabinoid that is a potent agonist of the CB1 receptor and has been sold online as a designer drug.While MDMB-CHMICA was initially sold under the name “MMB-CHMINACA”, the compound corresponding to this code name (i.e. the isopropyl instead of t-butyl analogue of MDMB-CHMINACA) has been identified on the designer drug market in 2015 as AMB-CHMINACA.
MDMB-CHMINACA is an indazole-based synthetic cannabinoid that acts as a potent agonist of the CB₁ receptor, and has been sold online as a designer drug. It was invented by Pfizer in 2008, and is one of the most potent cannabinoid agonists known, with a binding affinity of 0.0944 nM at CB₁, and an EC₅₀ of 0.330 nM
AMB-FUBINACA is an indazole-based synthetic cannabinoid that is a potent agonist for the cannabinoid receptors, with Kᵢ values of 10.04 nM at CB₁ and 0.786 nM at CB₂ and EC₅₀ values of 0.5433 nM at CB₁ and 0.1278 nM at CB₂, and has been sold online as a designer drug.
5F-ADB (also known as 5F-MDMB-PINACA) is an indazole-based synthetic cannabinoid from the indazole-3-carboxamide family, which has been used as an active ingredient in synthetic cannabis products and has been sold online as a designer drug. 5F-ADB is a potent agonist of the CB1 receptor, though it is unclear whether it is selective for this target. 5F-ADB was first identified in November 2014 from post-mortem samples taken from an individual who had died after using a product containing this substance. Subsequent testing identified 5F-ADB to have been present in a total of ten people who had died from unexplained drug overdoses in Japan between September 2014 and December 2014. 5F-ADB is believed to be extremely potent based on the very low levels detected in tissue samples, and appears to be significantly more toxic than earlier synthetic cannabinoid drugs that had previously been sold.
AKB48 are a Japanese idol girl group formed in 2005. as of July 28, 2019 the group consists of 102 members, divided among several teams: Team A with 23 members, Team K with 23 members, Team B with 23 members, and Team 4 with 28 members, Team 8 with 38 members, the last of which have 33 members serving concurrently with other AKB48 teams. There are Kenkyusei members, 13 of whom serve on specific teams as understudies, and three of whom were recruited as a group of general understudies.
Each of the teams has its own theme: according to member Misaki Iwasa, Team A represents freedom, Team K has a strong and powerful image, Team B is very idol-like with cutesy costumes, and Team 4 represents “the future of AKB48”. The member lineup often changes as when girls get older, they “graduate” from the group, and are replaced by members promoted from the trainees. Monica Hesse of The Washington Post describes the AKB48 audition process as “rolling American Idol-esque